Nexium ulcer approval
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca receives EU approval to market prescription proton pump inhibitor Nexium for the treatment of gastric ulcers and prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory (NSAID) therapy, firm announces Sept. 16. Research into the treatment of NSAID-associated upper GI side effects demonstrated that Nexium "can effectively heal gastric ulcers and prevent gastric and duodenal ulcers associated with long-term NSAID use, as well as relieve other painful upper GI symptoms such as epigastric pain, heartburn and acid reflux," according to Nexium NSAID program lead investigator Chris Hawkey, University Hospital, Nottingham, England. AstraZeneca applied for the same indications for Nexium in the U.S. earlier this year...